APOB and coronary artery disorder: However, a recent Mendelian randomized analysis showed that, in individuals with equal levels of non-HDL cholesterol, the development of coronary artery disease is not influenced by the number of Apo-B particles carried, suggesting that the clinical impact of lipid-lowering therapies is expected to be proportional to the reduction in non-HDL cholesterol rather than the reduction in Apo-B [46].